GLUE vs LZ
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GLUE · Monte Rosa Therapeutics$8.64 ▼ 3.03%
LZ · LegalZoom$4.47 ▼ 1.97%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GLUE -45.2%
- LZ -51.3%
Head to head
| Metric | GLUE | LZ |
|---|---|---|
| Price | $8.64 | $4.47 |
| Change today | ▼ 3.03% | ▼ 1.97% |
| Market cap | $738.29M | $738.26M |
| Return, 3 months | -37.3% | -25.5% |
| Return, year to date | -44.9% | -55.0% |
| Return, 1 year | -39.2% | -50.9% |
| P/E (TTM) | – | 40.6 |
| P/B | 1.5 | 5.5 |
| P/E percentile vs own 5y | 11th | 41st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +325.8% | +2.6% |
| Net profit growth (YoY) | +111.3% | +78.8% |
| Gross margin | – | 67.6% |
| Operating margin | -214.5% | 5.0% |
| Net margin | -186.2% | 2.6% |
| Return on equity | -35.3% | 12.1% |
| Analyst target vs. price | +191.0% | +28.6% |
| Analyst buy share | 100% | 0% |
| RSI (14) | 27 | 29 |
| 30-day volatility | 58.3% | 76.0% |
| Max drawdown, 1 year | -65.9% | -57.0% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Sell |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GLUE is the largest of the group by market value.
- GLUE has returned the most over the past year.
- GLUE is growing revenue fastest.
- LZ keeps the most profit per dollar of sales.
- GLUE has been the calmest stock over the last 30 days.